Splenic regrowth in sickle cell anaemia following hypertransfusion

Area of Science:

• Hematology
• Internal Medicine
• Pediatrics

Background:

• Sickle cell anaemia (SS) is a genetic blood disorder characterized by abnormal hemoglobin.
• Regular blood transfusions (hypertransfusion therapy) are a common treatment for managing severe complications of sickle cell anaemia.
• The spleen plays a crucial role in immune function and red blood cell filtration, and its function is often impaired in sickle cell disease.

Purpose of the Study:

• To investigate the phenomenon of splenic regrowth in adult patients with sickle cell anaemia receiving regular blood transfusions.
• To document the clinical, radiological, and histological evidence of splenic regrowth.
• To assess the potential clinical implications of splenic regrowth in this patient population.

Main Methods:

• Retrospective case series of five adult patients with homozygous sickle cell anaemia (SS).
• Patients received hypertransfusion therapy for indications including vaso-occlusive crises, chronic sickle lung, and renal function preservation.
• Splenic regrowth was assessed through clinical examination, radiological imaging (ultrasound), and histological analysis over a mean follow-up of 52 months.

Main Results:

• Five adult patients (23-34 years) with sickle cell anaemia showed evidence of splenic regrowth during hypertransfusion therapy.
• Splenomegaly was clinically apparent in one patient and documented on ultrasound in four patients.
• Two patients developed significant hypersplenism, indicating altered splenic function.

Conclusions:

• Splenic regrowth is a notable occurrence in hypertransfused adult patients with sickle cell anaemia.
• This phenomenon may have significant clinical implications, including the development of hypersplenism.
• Further research is needed to understand the mechanisms and clinical impact of splenic regrowth in sickle cell anaemia management.